ArticleApplied and environmental microbiology2008
Improved cloning vectors for bifidobacteria, based on the Bifidobacterium catenulatum pBC1 replicon.
Article in Applied and environmental microbiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Metabolic pathway analysis reveals hierarchical pentose sugar utilization and metabolic flexibility ofGut microbes · 2026Article
- Genetic and enzymatic basis of xylooligosaccharide metabolism byGut microbes · 2026Article
- Endogenous CRISPR-Based Removal of Tetracycline Resistance in Bifidobacterium animalis subsp. lactis Through a Safe-by-Design Approach.Microbial biotechnology · 2026Article
- Enhanced editing ofApplied and environmental microbiology · 2026Article
- Genetic engineering of gut commensals: heterologous protein expression inCurrent research in microbial sciences · 2026Article
- A CRISPRi Gene Regulation System for Bifidobacteria.Microbial biotechnology · 2025Article
- Establishment of CRISPR-Cas9 system in Bifidobacteria animalis AR668.Microbial cell factories · 2023Article
- Hacking Commensal Bacteria to Consolidate the Adaptive Mucosal Immune Response in the Gut-Lung Axis: Future Possibilities for SARS-CoV-2 Protection.Biotech (Basel (Switzerland)) · 2022Review
- A Resource for Cloning and Expression Vectors Designed for Bifidobacteria: Overview of Available Tools and Biotechnological Applications.Methods in molecular biology (Clifton, N.J.) · 2021Review
- Synthetic Biology Approaches to Engineer Probiotics and Members of the Human Microbiota for Biomedical Applications.Annual review of biomedical engineering · 2018Review
- A New Bifidobacteria Expression SysTem (BEST) to Produce and Deliver Interleukin-10 inFrontiers in microbiology · 2018Article
- Bifidobacterium breve as a delivery vector of IL-24 gene therapy for head and neck squamous cell carcinoma in vivo.Gene therapy · 2017Article
- The essential genomic landscape of the commensal Bifidobacterium breve UCC2003.Scientific reports · 2017Article
- Gene Replacement and Fluorescent Labeling to Study the Functional Role of Exopolysaccharides inFrontiers in microbiology · 2017Article
- A single mutation in the gene responsible for the mucoid phenotype of Bifidobacterium animalis subsp. lactis confers surface and functional characteristics.Applied and environmental microbiology · 2015Article
- The genome of Bifidobacterium pseudocatenulatum IPLA 36007, a human intestinal strain with isoflavone-activation activity.Gut pathogens · 2014Article
- Characterization of plasmid pML21 of Enterococcus faecalis ML21 from koumiss.Current microbiology · 2013Article
- Accessing the inaccessible: molecular tools for bifidobacteria.Applied and environmental microbiology · 2012Review
- A bile-inducible membrane protein mediates bifidobacterial bile resistance.Microbial biotechnology · 2012Article
- Development of a double-crossover markerless gene deletion system in Bifidobacterium longum: functional analysis of the α-galactosidase gene for raffinose assimilation.Applied and environmental microbiology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study reports the development of several cloning vectors for bifidobacteria based on the replicon of pBC1, a cryptic plasmid from Bifidobacterium catenulatum L48 thought to replicate via the theta mode. These vectors, in which antibiotic resistance genes encoding either erythromycin or tetracycline resistance acted as selection markers, were able to replicate in a series of eight Bifidobacterium species at frequencies ranging from 4.0 x 10(1) to 1.0 x 10(5) transformants microg(-1) but not in Lactococcus lactis or Lactobacillus casei. They showed a relative copy number of around 30 molecules per chromosome equivalent and a good segregational stability, with more than 95% of the cells retaining the vectors after 80 to 100 generations in the absence of selection. Vectors contain multiple cloning sites of different lengths, and the lacZalpha peptide gene was introduced into one of the molecules, thus allowing the easy selection of colonies harboring recombinant plasmids in Escherichia coli. The functionality of the vectors for engineering Bifidobacterium strains was assessed by cloning and examining the expression of an alpha-l-arabinofuranosidase gene belonging to Bifidobacterium longum. E. coli and Bifidobacterium pseudocatenulatum recombinant clones were stable and showed an increase in alpha-arabinofuranosidase activity of over 100-fold compared to that of the untransformed hosts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.